Medicare AdvantageBilling CodesMedium impact
MA07.056f, Photodynamic Therapy (PDT) Using Levulan® Kerastick® or Ameluz® (Aminolevulinic Acid HCl [ALA])
Independence Blue Cross·Dermatology, Oncology, Pharmacy·Pharmacy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
Independence Blue Cross has reissued Medicare Advantage Policy MA07.056f with a minor update effective 01/01/2026: HCPCS code J7309 has been terminated and removed from the policy. The coverage criteria for photodynamic therapy using Levulan® Kerastick® or Ameluz® remain unchanged. Billing teams must verify they are no longer billing with the discontinued J7309 code and use only the active codes J7308 or J7345.
Action Required
By 01/01/2026: Billing team must remove HCPCS code J7309 from all billing systems, templates, and billing software for Independence Blue Cross Medicare Advantage claims. Update billing software rules and encounter forms to prevent accidental selection of J7309. For future PDT billing, use only J7308 (aminolevulinic acid HCl 20%, 354 mg) or J7345 (aminolevulinic acid HCl 10% gel, 10 mg). Verify all active claims do not include J7309. Claims submitted with the terminated J7309 code will be denied or require correction.